Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225039 · ClinicalTrials.gov registry record · Phase 2
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT04225039 is a Phase 2 study of Glioblastoma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 39 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04225039, a Phase 2 study of Glioblastoma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
Conditions Studied
Interventions
- DRUG INCAGN01876
- DRUG INCMGA00012
- DRUG SRS
- PROCEDURE Brain surgery
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2029-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225039
The ClinicalTrials.gov registry entry for NCT04225039 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which INCAGN01876 is the first listed.
NCT04225039 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04225039 about?
NCT04225039 is a clinical study titled "Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma". This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a ro...
What is the current status of trial NCT04225039?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2020-06-23. Estimated completion is 2029-04-30.
What conditions does trial NCT04225039 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04225039?
The interventions under investigation include: INCAGN01876 (DRUG), INCMGA00012 (DRUG), SRS (DRUG), Brain surgery (PROCEDURE).
Who is sponsoring clinical trial NCT04225039?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04225039 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.